Trials / Completed
CompletedNCT04536961
A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
A Phase 1, Open-label, Crossover Study to Evaluate the Pharmacokinetics of BMS-986165 Administered as Various Prototypic Solid Tablet Formulations in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth as various solid tablet prototypes, by healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Reference Treatment- BMS-986165-01 | Specified dose on specified days |
| DRUG | Prototype BMS-986165 | Specified dose on specified days |
| DRUG | Famotidine | Specified dose on specified days |
| OTHER | Alcohol | Specified quantity on specified days |
Timeline
- Start date
- 2020-09-10
- Primary completion
- 2020-12-25
- Completion
- 2020-12-25
- First posted
- 2020-09-03
- Last updated
- 2021-10-06
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04536961. Inclusion in this directory is not an endorsement.